DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Navarro Sarabia, Federico ^a   Ruiz Montesinos, Dolores ^a   Hernandez, Blanca ^a   Navarro Compán, Victoria ^a   Marsal, Sara ^b   Barcelo, Mireia ^b   Perez Pampín, Eva ^c   Gámez Reino, Juan J ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DATA BASE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; INSTRUMENTATION; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RASH; RHEUMATOID ARTHRITIS; SPAIN; TREATMENT OUTCOME; TUBERCULOSIS; UNIVERSITY HOSPITAL; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VASCULITIS; DRUG ADMINISTRATION; DRUG ANTAGONISM; MIDDLE AGED; PREDICTION AND FORECASTING; QUESTIONNAIRE; TIME; TREATMENT FAILURE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SPAIN; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69049106539     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-91     Document Type: Article

References (48)

1. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes. EC Keystone, Nature Clin Pract Rheumatol 2006 2 594 601 10.1038/ncprheum0340
2. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. L Carmona JJ Gámez-Reino BIOBADASER Group, Arthritis Res Ther 2006 8 R72 16620398 10.1186/ar1941
3. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. D Tracey L Klareskog EH Sasso JG Salfeld PP Tak, Pharmacol Ther 2008 117 244 279 10.1016/j.pharmthera.2007.10.001 18155297
4. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. SB Cohen P Emery MW Greenwald M Dougados RA Furie MC Genovese EC Keystone JE Loveless GR Burmester MW Cravets EW Hessey T Shaw MC Totoritis, Arthritis Rheum 2006 54 2793 2806 10.1002/art.22025 16947627
5. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. P Emery E Keystone HP Tony A Cantagrel R van Vollenhoven A Sanchez E Alecock J Lee J Kremer, Ann Rheum Dis 2008 67 1516 23 10.1136/ard.2008.092932 18625622
6. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. MC Genovese M Schiff M Luggen JC Becker R Aranda J Teng T Li N Schmidely M Le Bars M Dougados, Ann Rheum Dis 2008 67 547 54 10.1136/ard.2007.074773 17921185
7. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. KL Hyrich M Lunt WG Dixon KD Watson DP Symmons BSR Biologics Register, Rheumatology (Oxford) 2008 47 1000 5 18420660 10.1093/rheumatology/ken127
8. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized double-blind, placebo-c (sic) [abstract]. J Smolen J Kay MK Doyle R Landewe EL Matteson J Wollenhaupt N Gaylis F Murphy J Neal O Zamani Y Zhou S Visvanathan EC Hsia MU Rahman, Ann Rheum Dis 2008 67 suppl II 50
9. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. JA Karlsson LE Kristensen MC Kapetanovic A Gulfe T Saxne P Geborek, Rheumatology (Oxford) 2008 47 507 513 10.1093/rheumatology/ken034 18304941
10. Effectiveness of a switch to a second anti-TNF-α in primary nonresponders, secondary nonresponders and failure due to adverse events. [abstract]. M Blom W Kievit J Fransen IH Kuper M van der Laar D de Rooj C de Gendt TL Jansen, Arthritis Rheum 2007 56 suppl S165
11. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The OPPOSITE study. DE Furst N Gaylis V Bray E Olech D Yocum J Ritter M Weisman DJ Wallace J Crues D Khanna G Eckel N Yeilding P Callegari S Visvanathan J Rojas R Hegedus L George K Mamun K Gilmer O Troum, Ann Rheum Dis 2007 66 893 9 10.1136/ard.2006.068304 17412737
12. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. A Finckh A Ciurea L Brulhart D Kyburz B Möller S Dehler S Revaz J Dudler C Gabay, Arthritis Rheum 2004 51 301 2 10.1002/art.20242 15077278
13. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. MH Buch SJ Bingham V Bejarano D Bryer J White R Reece M Quinn P Emery, Arthritis Rheum 2007 57 448 53 10.1002/art.22617 17394231
14. Switching TNF{alpha} antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a five-year period. F Conti F Ceccarelli E Marocchi L Magrini F Romana Spinelli A Spadaro R Scrivo G Valesini, Ann Rheum Dis 2007 66 1393 7 10.1136/ard.2007.073569 17613555
15. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? E Hjardem M Ostergaard J Pødenphant U Tarp LS Andersen J Bing E Peen HM Lindegaard VS Ringsdal A Rødgaard J Skøt A Hansen HH Mogensen J Unkerskov ML Hetland, Ann Rheum Dis 2007 66 1184 1189 10.1136/ard.2006.054742 17389656
16. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. KL Hyrich M Lunt KD Watson DP Symmons AJ Silman, Arthritis Rheum 2007 56 13 20 10.1002/art.22331 17195186
17. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. F Iannone F Trotta C Montecucco R Giacomelli M Galeazzi M Matucci-Cerinic C Ferri M Cutolo L Maria Bambara G Triolo G Ferraccioli G Valentini G Lapadula GISEA (Gruppo Italiano per lo Studio delle Early Arthritis), Ann Rheum Dis 2007 66 249 252 10.1136/ard.2006.058776 16837489
18. Adalimumab in severe rheumatoid arthritis after failure of two anti-TNF agents: a prospective 1-year follow-up study of 15 patients. F Atzeni P Sarzi-Puttini M Antivalle M Turiel M Carrabba, Ann Rheum Dis 2006 65 Suppl II 630
19. Efficacy and safety of adalimumab (HUMIRA®) in 899 patients with rheumatoid arthritis who previously failed etanercerpt and/or infliximab in clinical practice [abstract]. S Bombardieri F McKenna AA Drosos BA Michel D Hartz U Oezer, Ann Rheum Dis 2006 65 Suppl II 178
20. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. F Cantini L Niccoli M Benucci D Chindamo C Nannini I Olivieri A Padula C Salvarini, Arthritis Rheum 2006 55 812 6 10.1002/art.22236 17013842
21. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. JJ Gomez-Reino L Carmona, Arthritis Res Ther 2006 8 R29 Epub 2006 Jan 6 16507128 10.1186/ar1881
22. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. SN Nikas PV Voulgari Y Alamanos CG Papadopoulos AI Venetsanopoulou AN Georgiadis AA Drosos, Ann Rheum Dis 2006 65 257 260 15975964 10.1136/ard.2005.039099
23. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. E Solau-Gervais N Laxenaire B Cortet S Dubucquoi B Duquesnoy RM Flipo, Rheumatology (Oxford) 2006 45 1121 1124 10.1093/rheumatology/kel054 16510526
24. Disease characteristics of patients with rheumatoid arthritis that failed to respond to infliximab and the response to etanercept therapy: preliminary data from EMBARK study. CO Bingham PB Haraoui WFC Rigby V Montalvo-Lugo T Chon, Ann Rheum Dis 2005 64 Suppl III 172
25. Research in Active Rheumatoid Arthritis (ReAct) Study Group Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. S Bombardieri AA Ruiz P Fardellone P Geusens F McKenna K Unnebrink U Oezer S Kary H Kupper GR Burmester, Rheumatology (Oxford) 2007 46 1191 9 10.1093/rheumatology/kem091 17504821
26. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. GR Burmester X Mariette C Montecucco I Monteagudo-Sáez M Malaise AG Tzioufas JW Bijlsma K Unnebrink S Kary H Kupper, Ann Rheum Dis 2007 66 732 9 10.1136/ard.2006.066761 17329305
27. Switching from infliximab or adalimumab to etanercept 50 Mg/once weekly in resistant or intolerant patients with rheumatoid arthritis: 24-week results. F Cantini L Niccoli G Porciello, Arthritis Rheum 2005 52 suppl S560
28. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. G Cohen N Courvoisier JD Cohen S Zaltni J Sany B Combe, Clin Exp Rheumatol 2005 23 795 800 16396697
29. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. C Delaunay V Farrenq A Marini-Portugal JD Cohen X Chevalier P Claudepierre, J Rheumatol 2005 32 2183 2185 16265699
30. Adalimumab (HUMIRA®) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment. AE Van der Bijl FC Breedveld C Antoni JR Kalden S Kary GR Burmester K Unnebrink H Kupper, Ann Rheum Dis 2005 64 Suppl III 428
31. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. MC Wick S Ernestam S Lindblad J Bratt L Klareskog RF van Vollenhoven, Scand J Rheumatol 2005 34 353 358 10.1080/03009740510026887 16234182
32. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. MM Katsicas RA Russo, Clin Exp Rheumatol 2005 23 545 548 16095128
33. Switching anti-TNF therapy: real-world outcome of patients with rheumatoid arthritis who failed either infliximab or etanercept treatment and switched to another TNF inhibitor [abstract]. EC Keystone JL Perruquet RW Lidman, Arthritis Rheum 2004 51 Suppl S990
34. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. EG Favalli M Arreghini C Arnoldi B Panni A Marchesoni S Tosi I Pontikaki, Arthritis Rheum 2004 51 301 302 10.1002/art.20242 15077278
35. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. KE Hansen JP Hildebrand MC Genovese JJ Cush S Patel DA Cooley SB Cohen RE Gangnon MH Schiff, J Rheumatol 2004 31 1098 1102 15170921
36. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. B Haraoui EC Keystone JC Thorne JE Pope I Chen CG Asare JA Leff, J Rheumatol 2004 31 2356 2359 15570634
37. Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab. R Sanmarti JA Gomez-Puerta JR Rodriguez-Cros C Albaladejo J Munoz-Gomez JD Canete, Med Clin (Barc) 2004 122 321 324 10.1157/13059029 15033049
38. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Y Yazici D Erkan, Ann Rheum Dis 2004 63 607 608 15082503
39. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? HT Ang S Helfgott, J Rheumatol 2003 30 2315 2318 14677170
40. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. R van Vollenhoven A Harju S Brannemark L Klareskog, Ann Rheum Dis 2003 62 1195 1198 14644858 10.1136/ard.2003.009589
41. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha. O Brocq Y Plubel V Breuil C Grisot P Flory A Mousnier L Euller-Ziegler, Presse Med 2002 31 1836 1839 12496713
42. Experience with commercial remicade (infliximab) at a large community-based rheumatology practice [abstract]. W Shergy RM Phillips RE Hunt J Hernandez, Arthritis Rheum 2001 44 Suppl S81
43. Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. DE Beaton C Bombardier JN Katz JG Wright G Wells M Boers V Strand B Shea, J Rheumatol 2001 28 400 5 11246687
44. Infliximab and methotrexate in the treatment of rheumatoid arthritis. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden JS Smolen M Weisman P Emery M Feldmann GR Harriman RN Maini, N Engl J Med 2000 43 1594 602 10.1056/NEJM200011303432202
45. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. ME Weinblatt EC Keystone DE Furst LW Moreland MH Weisman CA Birbara LA Teoh SA Fischkoff EK Chartash, Arthritis Rheum 2003 48 35 45 10.1002/art.10697 12528101
46. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. ME Weinblatt JM Kremer AD Bankhurst KJ Bulpitt RM Fleischmann RI Fox CG Jackson M Lange DJ Burge, N Engl J Med 1999 340 253 9 10.1056/NEJM199901283400401 9920948
47. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. D Aletaha MM Ward, Ann Rheum Dis 2006 65 227 33 15975967 10.1136/ard.2005.038513
48. Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis: B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. A Finckh A Ciurea L Brulhart D Kyburz B Möller S Dehler S Revaz J Dudler C Gabay, Arthritis Rheum 2007 56 1417 23 10.1002/art.22520 17469098